)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
LAVA Therapeutics
LAVA Therapeutics (LVTX) investor relations material
LAVA Therapeutics has been acquired by XOMA Corporation
LAVA Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary9 Dec, 2025
Executive summary
Entered into a share purchase agreement with XOMA Royalty Corporation for acquisition via tender offer, including a cash payment and contingent value rights (CVRs) per share.
Amended agreement in October 2025 reduced minimum closing net cash condition and extended offer expiration.
Discontinued all clinical and nonclinical programs, including LAVA-1207 and LAVA-1266, as part of a strategic restructuring.
Workforce reduced by approximately 71% to 10 full-time employees by September 30, 2025.
Financial highlights
Cash and cash equivalents were $49.7 million as of September 30, 2025, up from $35.0 million at December 31, 2024.
Net loss for the nine months ended September 30, 2025 was $19.3 million, compared to $21.2 million for the same period in 2024.
No revenue recognized in 2025; $7.0 million revenue recognized in 2024 from a Pfizer milestone.
Operating loss for the nine months ended September 30, 2025 was $22.4 million, down from $22.8 million in 2024.
Gain on extinguishment of borrowings of $5.2 million recognized in 2025 due to loan forgiveness.
Outlook and guidance
Future operations highly dependent on successful completion of the XOMA Transaction.
If the transaction is not completed, strategic alternatives including dissolution and liquidation may be pursued.
Cash and cash equivalents expected to be sufficient to fund planned expenditures for at least the next twelve months.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from LAVA Therapeutics
- Board recommends approval of XOMA acquisition, offering cash, CVR, and merger reorganization.LVTX
Proxy Filing - Acquisition for $1.16–$1.24 per share plus CVR, board support, EGM vote, and delisting planned.LVTXProxy Filing
- Board recommends shareholders approve sale for $1.04 plus CVR per share and post-offer merger.LVTXProxy Filing
- Board recommends approval of XOMA's $1.16–$1.24/share offer plus CVR and post-offer merger.LVTXProxy Filing
- AGM to vote on annual accounts, auditor, director reappointments, and share buyback authorization.LVTXProxy Filing
- AGM to vote on 2024 accounts, auditor, director reappointments, and share repurchase authority.LVTXProxy Filing
- AGM proposals include auditor changes, director reappointments, and share repurchase authorization.LVTXProxy Filing
- Tender offer for LAVA shares extended; shareholders to vote on acquisition before November 2025.LVTXProxy Filing
- Amended offer provides $1.04 per share plus CVR, with closing expected in Q4 2025.LVTXProxy Filing
- Shareholders to vote on acquisition offer involving cash and CVRs, pending key approvals.LVTXProxy Filing
LAVA Therapeutics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
LAVA Therapeutics N.V. is a biotechnology company focused on developing bispecific gamma-delta T cell engagers (TCEs) for cancer treatment. The company’s proprietary Gammabody platform is designed to activate the immune system by targeting gamma-delta T cells to recognize and destroy tumor cells. LAVA Therapeutics is advancing a pipeline of investigational therapies for hematologic and solid tumors through clinical research and industry collaborations. The company is headquartered in Utrecht, Netherlands, and its shares are listed on the NASDAQ.